TNFRSF18 and ovarian cancer: Although antagonist PD-1 or agonistic GITR mAbs can promote the rejection of some murinetumors, however, poorly immunogenic tumors such as ID8 ovarian cancer do not respond tosingle immunomodulating mAb therapy [29].